WebMar 31, 2024 · (Reuters) -Cytokinetics Inc said on Friday it would focus on its heart disease treatment after its amyotrophic lateral sclerosis (ALS) drug failed a late-stage study. The drug developer's move to employ resources freed up from the ALS project for its potential billion-dollar-plus heart drug sent its shares up more than 5%. Cytokinetics' … WebMar 27, 2024 · Cytokinetics is committed to our mission of developing potential medicines that may improve the healthspan of people living with cardiovascular and neuromuscular diseases of impaired muscle function. …
Mizuho Securities Keeps Their Buy Rating on Cytokinetics (CYTK)
WebApr 13, 2024 · The projected fair value for Cytokinetics is US$38.04 based on 2 Stage Free Cash Flow to Equity. Cytokinetics' US$34.05 share price indicates it is trading at similar levels as its fair value estimate WebMar 31, 2024 · Cytokinetics News More News. TipRanks 10h. Bank of America Securities Reaffirms Their Hold Rating on Cytokinetics (CYTK) ... Cytokinetics, Inc. is a biopharmaceutical company, which is focused on ... dai ethnic minority
Cytokinetics (CYTK) Dips 20% so Far in 2024 on Setbacks
WebApr 10, 2024 · It has been a rough year so far for late-stage biopharmaceutical company, Cytokinetics, Incorporated CYTK. Shares of the company have moved down 20.5% compared with the industry ’s decline of 4.7%. WebApr 10, 2024 · Cytokinetics currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. LGND - Free Report) , both sporting a Zacks Rank #1 at ... WebApr 7, 2024 · Latest Cytokinetics, Inc. Stock News. As of April 06, 2024, Cytokinetics, Inc. had a $3.4 billion market capitalization, putting it in the 78th percentile of companies in the Biotechnology & Medical Research industry. Cytokinetics, Inc. does not have a meaningful P/E due to negative earnings over the last 12 trailing months. ... dahlia plants in pots